Reduced disease progression risk with maintenance olaparib rechallenge in pretreated ovarian cancer

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site

Sep 17 / Springer Healthcare

Reduced disease progression risk with maintenance olaparib rechallenge in pretreated ovarian cancer

Oncology Ovarian Cancer ESMO-2021

Description

Mansoor Raza Mirza comments on the OReO/ENGOT Ov-38 trial looking at maintenance PARP inhibitor rechallenge in pretreated patients with ovarian carcinoma.

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.